Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings)

Aug 13, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Bio-Techne, presenting an average target of $83.0, a high estimate of $95.00, and a low estimate …

$83
OFF

Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings)

2 weeks from now

Aug 13, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Bio-Techne, presenting an average target of $83.0, a high estimate of $95.00, and a low estimate …

nasdaq.com

$39
OFF

Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

2 weeks from now

1 day ago · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $39.0, along with a high estimate of $52.00 and a low estimate …

nasdaq.com

$176.61
OFF

Deep Dive Into Advanced Micro Devices Stock: Analyst …

2 weeks from now

3 days ago · In the assessment of 12-month price targets, analysts unveil insights for Advanced Micro Devices, presenting an average target of $176.61, a high estimate of $250.00, and a low …

benzinga.com

$106.36
OFF

Deep Dive Into Popular Stock: Analyst Perspectives (11 Ratings)

2 weeks from now

Dec 20, 2024 · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $106.36, along with a high estimate of $117.00 and a low …

benzinga.com

$52
OFF

Rollins Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

2 weeks from now

Jan 6, 2025 · In the assessment of 12-month price targets, analysts unveil insights for Rollins, presenting an average target of $52.8, a high estimate of $58.00, and a low estimate of $48.00.

benzinga.com

FAQs about Deep Dive Into Bio-Techne Stock: Analyst Perspectives (4 Ratings) Coupon?

How do analysts evaluate Bio-Techne's market position?

Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Bio-Techne's future value. Comparing current and prior targets offers insights into analysts' evolving expectations. Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bio-Techne's market position. ...

Is Bio-Techne a good stock to buy?

Return on Assets (ROA): Bio-Techne's ROA stands out, surpassing industry averages. With an impressive ROA of 1.8%, the company demonstrates effective utilization of assets and strong financial performance. Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average. ...

What is the average price target for Bio-Techne?

This current average reflects an increase of 8.54% from the previous average price target of $79.00. A comprehensive examination of how financial experts perceive Bio-Techne is derived from recent analyst actions. ...

What is Bio-Techne's debt-to-equity ratio?

Debt Management: Bio-Techne's debt-to-equity ratio is below the industry average. With a ratio of 0.25, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors. ...

How did Bio-Techne perform in 3 months?

This could be influenced by factors such as growth expectations or operational capacity. Revenue Growth: Bio-Techne's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 3.16%. This signifies a substantial increase in the company's top-line earnings. ...

Why did Bio-Techne achieve a strong revenue growth rate?

This could be due to various factors, including perceived growth potential or operational scale. Revenue Growth: Over the 3 months period, Bio-Techne showcased positive performance, achieving a revenue growth rate of 0.37% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. ...